FDA approval history Drug class: BCR-ABL tyrosine kinase inhibitors Breastfeeding En español Patient resources Other brands Imkeldi Professional resources Gleevec prescribing information Imatinib (AHFS Monograph) Related treatment guides Chronic Myelogenous Leukemia Chronic Eosinophilic Leukemia Acute Lymphoblasti...
The US Food and Drug Administration (FDA) has GRANTED IMATINIB FULL APPROVAL AS AN ADJUVANT TREATMENT FOLLOWING SURGICAL REMOVAL OF CD117-POSITIVE GASTROINTESTINAL STROMAL TUMORS(GIST) in adult patients. The drug had received accelerated approval for this indication in 2008.The confirmatory, phase III...
Gleevec (imatinib mesylate) is a kinase inhibitor that inhibits a protein signal that causes cancer cell proliferation used to treat patients with hematological malignancies ormalignantsarcomas such as Philadelphia positive chronic myeloidleukemia, chronic myeloid leukemia in blast crisis, acute lymphoblastic ...
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.What to Read Next on Medscape News & Perspective To Choose the Best First-line Drug for CML, Consider Efficacy and Cost ...
FDA Approval for Gleevec for Children with Ph+ ALLdoi:10.1097/01.COT.0000427834.60711.5cOncology TimesOncology Times
Gleevec (imatinib mesylate) is a kinase inhibitor that inhibits a protein signal that causes cancer cell proliferation used to treat patients with hematological malignancies ormalignantsarcomas such as Philadelphia positive chronic myeloidleukemia, chronic myeloid leukemia in blast crisis, acute lymphoblastic...
doi:10.4161/cbt.5.7.3156NoneTaylor & FrancisCancer Biology & Therapy
Gleevec (imatinib mesylate) is a kinase inhibitor that inhibits a protein signal that causes cancer cell proliferation used to treat patients with hematological malignancies ormalignantsarcomas such as Philadelphia positive chronic myeloidleukemia, chronic myeloid leukemia in blast crisis, acute lymphoblastic...